DNA hypomethylation in cancer cells

Epigenomics

Volumn 1, Issue 2, 2009, Pages 239-259

  Ehrlich, Melanie ^a  

^a TULANE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Cancer; DNA methylation; DNA repeats; Genomic sequencing hypermethylation; Hypomethylation

Indexed keywords

BIOLOGICAL MODEL; CANCER STEM CELL; CPG ISLAND; DNA METHYLATION; GENE EXPRESSION REGULATION; GENETIC EPIGENESIS; GENETICS; HUMAN; METABOLISM; NEOPLASM; PATHOPHYSIOLOGY; PHYSIOLOGY; REVIEW;

CPG ISLANDS; DNA METHYLATION; EPIGENESIS, GENETIC; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MODELS, BIOLOGICAL; NEOPLASMS; NEOPLASTIC STEM CELLS;

EID: 77954661906     PISSN: 17501911     EISSN: 1750192X     Source Type: Journal    
DOI: 10.2217/EPI.09.33     Document Type: Review

References (251)

1. Gama-Sosa MA, Slagel VA, Trewyn RW et al.: The 5-methylcytosine content of DNA from human tumors. Nucleic Acids Res. 11, 6883-6894 (1983).
2. Feinberg AP, Vogelstein B: Hypomethylation distinguishes genes of some human cancers from their normal counterparts. Nature 301, 89-92 (1983).
3. Feinberg AP, Vogelstein B: Hypomethylation of ras oncogenes in primary human cancers. Biochem. Biophys. Res. Commun. 111, 47-54 (1983).
4. Bedford MT, van Helden PD: Hypomethylation of DNA in pathological conditions of the human prostate. Cancer Res. 47, 5274-5276 (1987).
5. Ehrlich M: DNA methylation in cancer: too much, but also too little. Oncogene 21, 5400-5413 (2002).
6. de Capoa A, Musolino A, Delia Rosa S et al.: DNA demethylation is directly related to tumour progression: evidence in normal, pre-malignant and malignant cells from uterine cervix samples. Oncol. Rep. 10, 545-549 (2003).
7. Brothman AR, Swanson G, Maxwell TM et al.: Global hypomethylation is common in prostate cancer cells: a quantitative predictor for clinical outcome? Cancer Genet. Cytogenet. 156, 31-36 (2005).
8. Seifert HH, Schmiemann V, Mueller M et al.: In situ detection of global DNA hypomethylation in exfoliative urine cytology of patients with suspected bladder cancer. Exp. Mol. Pathol. 82(3), 292-297 (2007).
9. Cadieux B, Ching TT, Vandenberg SR, Costello JF: Genome-wide hypomethylation in human glioblastomas associated with specific copy number alteration, methylenetetrahydrofolate reductase allele status, and increased proliferation. Cancer Res. 66, 8469-8476 (2006).
10. Graff JR, Herman JG, Lapidus RG et al.: E-cadherin expression is silenced by DNA hypermethylation in human breast and prostate carcinomas. Cancer Res. 55, 5195-5199 (1995).
11. Melki JR, Vincent PC, Clark SJ: Concurrent DNA hypermethylation of multiple genes in acute myeloid leukemia. Cancer Res. 59, 3730-3740 (1999).
12. Costello JF, Fruhwald MC, Smiraglia DJ et al.: Aberrant CpG-island methylation has non-random and tumor-type-specific patterns. Nat. Genet. 24, 132-138 (2000).
13. Issa JP: CpG island methylator phenotype in cancer. Nat. Rev. Cancer A, 988-993 (2004).
14. Pfeifer GP, Rauch TA: DNA methylation patterns in lung carcinomas. Semin. Cancer Biol. 19, 181-187 (2009).
15. Nguyen C, Liang G, Nguyen TT et al.: Susceptibility of nonpromoter CpG islands to de novo methylation in normal and neoplastic cells. J. Natl Cancer Inst. 93, 1465-1472 (2001).
16. Cheng P, Schmutte C, Cofer KF, Felix JC, Yu MC, Dubeau L: Alterations in DNA methylation are early, but not initial, events in ovarian tumorigenesis. Br. J. Cancer 75, 396-402 (1997).
17. Ehrlich M, Woods C, Yu M et al.: Quantitative analysis of association between DNA hypermethylation, hypomethylation, and DNMT RNA levels in ovarian tumors. Oncogene 25, 2636-2645 (2006).
18. Wahlfors J, Hiltunen H, Heinonen K, Hamalainen E, Alhonen L, Janne J: Genomic hypomethylation in human chronic lymphocytic leukemia. Blood 80, 2074-2080 (1992).
19. Lin CH, Hsieh SY, Sheen IS et al: Genome-wide hypomethylation in hepatocellular carcinogenesis. Cancer Res. 61, 4238-4243 (2001).
20. Kim Y-I, Giuliano A, Hatch KD et al.: Global DNA hypomethylation increases progressively in cervical dysplasia and carcinoma. Cancer 74, 893-899 (1994).
21. Feinberg AP, Gehrke CW, Kuo KC, Ehrlich M: Reduced genomic 5-methylcytosine content in human colonic neoplasia. Cancer Res. 48, 1159-1161 (1988).
22. Ehrlich M, Jiang G, Fiala ES et al.: Hypomethylation and hypermethylation of DNA in Wilms tumors. Oncogene 21, 6694-6702 (2002).
23. Morey SR, Smiraglia DJ, James SR et al.: DNA methylation pathway alterations in an autochthonous murine model of prostate cancer. Cancer Res. 66, 11659-11667 (2006).
24. Nishiyama R, Qi L, Tsumagari K et al.: A DNA repeat, NBL2, is hypermethylated in some cancers but hypomethylated in others. Cancer Biol. Ther. 4, 440-448 (2005).
25. Gama-Sosa MA, Wang RY, Kuo KC, Gehrke CW, Ehrlich M: The 5-methylcytosine content of highly repeated sequences in human DNA. Nucleic Acids Res. 11, 3087-3095(1983).
26. Smiraglia DJ, Rush LJ, Fruhwald MC et al.: Excessive CpG island hypermethylation in cancer cell lines versus primary human malignancies. Hum. Mol. Genet. 10, 1413-1419(2001).
27. Hoffmann MJ, Schulz WA: Causes and consequences of DNA hypomethylation in human cancer. Biochem. Cell Biol. 83, 296-321 (2005).
28. Weisenberger DJ, Campan M, Long TI et al.: Analysis of repetitive element DNA methylation by MethyLight. Nucleic Acids Res. 33, 6823-6836 (2005).
29. Narayan A, Ji W, Zhang X-Y et al.: Hypomethylation of pericentromeric DNA in breast adenocarcinomas. Int. J. Cancer 77, 833-838 (1998).
30. Qu G, Dubeau L, Narayan A, Yu M, Ehrlich M: Satellite DNA hypomethylation vs. overall genomic hypomethylation in ovarian epithelial tumors of different malignant potential. Mut. Res. 423, 91-101 (1999).
31. Qu G, Grundy PE, Narayan A, Ehrlich M: Frequent hypomethylation in Wilms tumors of pericentromeric DNA in chromosomes 1 and 16. Cancer Genet. Cytogenet. 109, 34-39 (1999).
32. Florl AR, Steinhoff C, Muller M et al.: Coordinate hypermethylation at specific genes in prostate carcinoma precedes LINE-1 hypomethylation. Br. J. Cancer 91, 985-994 (2004).
33. Kim MJ, White-Cross JA, Shen L, Issa JP, Rashid A: Hypomethylation of long interspersed nuclear element-1 in hepatocellular carcinomas. Mod. Pathol. 22, 442-449 (2009).
34. Rodriguez J, Vives L, Jorda M et al.: Genome-wide tracking of unmethylated DNA Alu repeats in normal and cancer cells. Nucleic Acids Res. 36, 770-784 (2008).
35. Widschwendter M, Jiang G, Woods C et al.: DNA hypomethylation and ovarian cancer biology. Cancer Res. 64, 4472-4480 (2004).
36. Ehrlich M, Hopkins N, Jiang G et al: Satellite hypomethylation in karyotyped Wilms tumors. Cancer Genet. Cytogenet. 141, 97-105 (2003).
37. Rauch TA, Zhong X, Wu X et al: Highresolution mapping of DNA hypermethylation and hypomethylation in lung cancer. Proc. Natl Acad. Sci. USA 105, 252-257 (2008).
38. Goelz SE, Vogelstein B, Hamilton SR, Feinberg AP: Hypomethylation of DNA from benign and malignant human colon neoplasms. Science 228, 187-190 (1985).
39. Wasson GR, McGlynn AP, McNulty H et al: Global DNA and p53 region-specific hypomethylation in human colonic cells is induced by folate depletion and reversed by folate supplementation. J Nutr. 136, 2748-2753 (2006).
40. Kress C, Thomassin H, Grange T: Active cytosine demethylation triggered by a nuclear receptor involves DNA strand breaks. Proc. Natl Acad. Sci. USA 103, 11112-11117 (2006).
41. Wilson AS, Power BE, Molloy PL: DNA hypomethylation and human diseases. Biochim. Biophys. Acta 1775, 138-162 (2007).
42. Lindsey JC, Lusher ME, Anderton JA, Gilbertson RJ, Ellison DW, Clifford SC: Epigenetic deregulation of multiple S100 gene family members by differential hypomethylation and hypermethylation events in medulloblastoma. Br. J. Cancer 97, 267-274 (2007).
43. Grunau C, Brun ME, Rivals I et al.: BAGE hypomethylation, a new epigenetic biomarker for colon cancer detection. Cancer Epidemiol. Biomarkers Prev. 17, 1374-1379 (2008).
44. Ortmann CA, Eisele L, Nuckel H et al.: Aberrant hypomethylation of the cancer-testis antigen PRAME correlates with PRAME expression in acute myeloid leukemia. Ann. Hematol. 87, 809-818 (2008).
45. Novak P, Jensen T, Oshiro MM, Watts GS, Kim CJ, Futscher BW: Agglomerative epigenetic aberrations are a common event in human breast cancer. Cancer Res. 68, 8616-8625 (2008).
46. Pakneshan P, Tetu B, Rabbani SA: Demethylation of urokinase promoter as a prognostic marker in patients with breast carcinoma. Clin. Cancer Res. 10, 3035-3041 (2004).
47. Pulukuri SM, Estes N, Patel J, Rao JS: Demethylation-linked activation of urokinase plasminogen activator is involved in progression of prostate cancer. Cancer Res. 67, 930-939 (2007).
48. Ateeq B, Unterberger A, Szyf M, Rabbani SA: Pharmacological inhibition of DNA methylation induces proinvasive and prometastatic genes in vitro and in vivo. Neoplasia 10, 266-278 (2008).
49. De Smet C, Lurquin C, Lethe B, Martelange V, Boon T: DNA methylation is the primary silencing mechanism for a set of germ line- and tumor-specific genes with a CpG-rich promoter. Mol. Cell. Biol. 19, 7327-7335 (1999).
50. Rosty C, Ueki T, Argani P et al: Overexpression of S100A4 in pancreatic ductal adenocarcinomas is associated with poor differentiation and DNA hypomethylation. Am. J. Pathol. 160, 45-50 (2002).
51. Sato N, Fukushima N, Matsubayashi H, Goggins M: Identification of maspin and S100P as novel hypomethylation targets in pancreatic cancer using global gene expression profiling. Oncogene 23, 1531-1538 (2004).
52. Lee YM, Lee J Y, Kim MJ et al.: Hypomethylation of the protein gene product 9.5 promoter region in gallbladder cancer and its relationship with clinicopathological features. Cancer Sci. 97, 1205-1210 (2006).
53. Ye L, Li X, Kong X et al.: Hypomethylation in the promoter region of POMC gene correlates with ectopic overexpression in thymic carcinoids. J. Endocrinol. 185, 337-343 (2005).
54. Kaneda A, Tsukamoto T, Takamura-Enya T et al: Frequent hypomethylation in multiple promoter CpG islands is associated with global hypomethylation, but not with frequent promoter hypermethylation. Cancer Sci. 95, 58-64 (2004).
55. Grunau C, Sanchez C, Ehrlich M et al: Frequent DNA hypomethylation in the human juxtacentromeric BAGE loci in cancer. Genes Chrom. Cancer 43, 11-24 (2005).
56. Salem C, Liang G, Tsai YC et al.: Progressive increases in de novo methylation of CpG islands in bladder cancer. Cancer Res. 60, 2473-2476 (2000).
57. Fruhwald MC, O'Dorisio MS, Dai Z et al: Aberrant promoter methylation of previously unidentified target genes is a common abnormality in medulloblastomas - implications for tumor biology and potential clinical utility. Oncogene 20, 5033-5042 (2001).
58. Brock MV, Gou M, Akiyama Y et al.: Prognostic importance of promoter hypermethylation of multiple genes in esophageal adenocarcinoma. Clin. Cancer Res. 9, 2912-2919 (2003).
59. Jackson K, Yu M, Arakawa K et al.: DNA hypomethylation is prevalent even in low-grade breast cancers. Cancer Biol. Ther. 3, 1225-1231 (2004).
60. Suzuki K, Suzuki I, Leodolter A et al.: Global DNA demethylation in gastrointestinal cancer is age dependent and precedes genomic damage. Cancer Cell 9, 199-207 (2006).
61. Roman-Gomez J, Jimenez-Velasco A, Agirre X et al.: Repetitive DNA hypomethylation in the advanced phase of chronic myeloid leukemia. Leuk. Res. 32, 487-490 (2008).
62. Park SY, Yoo EJ, Cho NY, Kim N, Kang GH: Comparison of CpG island hypermethylation and repetitive DNA hypomethylation in premalignant stages of gastric cancer, stratified for Helicobacter pylori infection. J. Pathol. (2009) (Epub ahead of print).
63. Markt ID, Cheng J, Liang G, Shibata D, Laird PW, Jones PA: Global and gene-specific epigenetic patterns in human bladder cancer genomes are relatively stable in vivo and in vitro over time. Cancer Res. 61, 5875-5884 (2001).
64. Roman-Gomez J, Jimenez-Velasco A, Agirre X et al: Promoter hypomethylation of the LINE-1 retrotransposable elements activates sense/antisense transcription and marks the progression of chronic myeloid leukemia. Oncogene 24, 7213-7223 (2005).
65. Shen L, Fang J, Qiu D et al: Correlation between DNA methylation and pathological changes in human hepatocellular carcinoma. Hepatogastroenterology 45, 1753-1759 (1998).
66. Soares J, Pinto AE, Cunha CV et al.: Global DNA hypomethylation in breast carcinoma: correlation with prognostic factors and tumor progression. Cancer 85, 112-118 (1999).
67. Santourlidis S, Florl A, Ackermann R, Wim HC, Schulz WA: High frequency of alterations in DNA methylation in adenocarcinoma of the prostate. Prostate 39, 166-174 (1999).
68. Itano O, Ueda M, Kikuchi K et al.: Correlation of postoperative recurrence in hepatocellular carcinoma with demethylation of repetitive sequences. Oncogene 21, 789-797 (2002).
69. Ehrlich M: The controversial denouement of vertebrate DNA methylation research. Biochemistry (Mosc.) 70, 568-575 (2005).
70. Richardson BC: Role of DNA methylation in the regulation of cell function: autoimmunity, aging and cancer. J. Nutr. 132, S2401-S2405 (2002).
71. Ehrlich M: The ICF syndrome, a DNA methyltransferase 3B deficiency and immunodeficiency disease. Clin. Immunol. 109, 17-28 (2003).
72. Gisselsson D, Shao C, Tuck-Muller C et al.: Interphase chromosomal abnormalities and mitotic missegregation of hypomethylated sequences in ICF syndrome cells. Chromosoma 114, 118-126(2005).
73. Ehrlich M: Expression of various genes is controlled by DNA methylation during mammalian development. J. Cell Biochem. 88, 899-910 (2003).
74. Kersh EN, Fitzpatrick DR, Murali-Krishna K et al.: Rapid demethylation of the IFN-γ gene occurs in memory but not naive CD8 T cells. J. Immunol. 176, 4083-4093 (2006).
75. Chang HS, Anway MD, Rekow SS, Skinner MK: Transgenerational epigenetic imprinting of the male germline by endocrine disruptor exposure during gonadal sex determination. Endocrinology 147, 5524-5541 (2006).
76. Murayama A, Sakura K, Nakama M et al.: A specific CpG site demethylation in the human interleukin 2 gene promoter is an epigenetic memory. EMBO J. 25, 1081-1092 (2006).
77. Dolinoy DC, Weidman JR, Jirtle RL: Epigenetic gene regulation: linking early developmental environment to adult disease. Reprod. Toxicol. 23(3), 297-307 (2006).
78. Reichard JF, Schnekenburger M, Puga A: Long term low-dose arsenic exposure induces loss of DNA methylation. Biochem. Biophys. Res. Commun. 352, 188-192 (2007).
79. Champagne FA, Curley JP: Epigenetic mechanisms mediating the long-term effects of maternal care on development. Neurosci. Biobehav. Rev. 33, 593-600 (2009).
80. Baccarelli A, Wright RO, Bollati V et al.: Rapid DNA methylation changes after exposure to traffic particles. Am. J. Respir. Crit. Care Med. 179, 572-578 (2009).
81. Gupta A, Godwin AK, Vanderveer L, Lu A, Liu J: Hypomethylation of thes ynuclein γ gene CpG island promotes its aberrant expression in breast carcinoma and ovarian carcinoma. Cancer Res. 63, 664-673 (2003).
82. Ogishima T, Shiina H, Breault JE et al.: Increased heparanase expression is caused by promoter hypomethylation and upregulation of transcriptional factor early growth response-1 in human prostate cancer. Clin. Cancer Res. 11, 1028-1036(2005).
83. Fan T, Schmidtmann A, Xi S et al.: DNA hypomethylation caused by Lsh deletion promotes erythroleukemia development. Epigenetics 3, 134-142(2008).
84. Ehrlich M, Gama-Sosa M, Huang L-H et al: Amount and distribution of 5-methylcytosine in human DNA from different types of tissues or cells. Nucleic Acids Res. 10, 2709-2721 (1982).
85. Gama-Sosa MA, Midgett RM, Slagel VA et al.: Tissue-specific differences in DNA methylation in various mammals. Biochim. Biophys. Acta 740, 212-219 (1983).
86. Khalkhali-Ellis Z: Maspin: the new frontier. Clin. Cancer Res. 12, 7279-7283 (2006).
87. Kim JY, Siegmund KD, Tavarc S, Shibata D: Age-related human small intestine methylation: evidence for stem cell niches. BMC Med. 3, 10 (2005).
88. Eads CA, Lord RV, Kurumboor SK et al.: Fields of aberrant CpG island hypermethylation in Barrett's esophagus and associated adenocarcinoma. Cancer Res. 60, 5021-5026(2000).
89. Fanelli M, Caprodossi S, Ricci-Vitiani L et al.: Loss of pericentromeric DNA methylation pattern in human glioblastoma is associated with altered DNA methyltransferases expression and involves the stem cell compartment. Oncogene 27, 358-365 (2008).
90. Iacobuzio-Donahue CA: Epigenetic changes in cancer. Annu. Rev. Pathol. 4, 229-249 (2009).
91. Plass C, Soloway PD: DNA methylation, imprinting and cancer. Eur. J. Hum. Genet. 10, 6-16 (2002).
92. Yamada Y, Watanabe H, Miura F et al.: A comprehensive analysis of allelic methylation status of CpG islands on human chromosome 21q. Genome Res. 14, 247-266 (2004).
93. Ahuja N, Li Q, Mohan AL, Baylin SB, Issa JP: Aging and DNA methylation in colorectal mucosa and cancer. Cancer Res. 58, 5489-5494 (1998).
94. Flanagan JM, Popendikyte V, Pozdniakovaite N et al.: Intra- and interindividual epigenetic variation in human germ cells. Am. J. Hum. Genet. 79, 67-84 (2006).
95. Tra J, Kondo T, Lu Q, Kuick R, Hanash S, Richardson B: Infrequent occurrence of age-dependent changes in CpG island methylation as detected by restriction landmark genome scanning. Mech. Ageing Dev. 123, 1487-1503 (2002).
96. Issa JP: Age-related epigenetic changes and the immune system. Clin. Immunol. 109, 103-108 (2003).
97. Eckhardt F, Lewin J, Cortese R et al.: DNA methylation profiling of human chromosomes 6, 20 and 22. Nat. Genet. 38, 1378-1385 (2006).
98. Kristensen LS, Hansen LL: PCR-based methods for detecting single-locus DNA methylation biomarkers in cancer diagnostics, prognostics, and response to treatment. Clin. Chem. 55, 1471-1483 (2009).
99. Sepulveda AR, Jones D, Ogino S et al.: CpG methylation analysis - current status of clinical assays and potential applications in molecular diagnostics: a report of the association for molecular pathology. J. Mol. Diagn. 11, 266-278 (2009).
100. Chu T, Burke B, Bunce K, Surti U, Allen Hogge W, Peters DG: A microarray-based approach for the identification of epigenetic biomarkers for the noninvasive diagnosis of fetal disease. Prenat. Diagn. 29(11), 1020-1030 (2009).
101. Rodenhiser DI, Andrews J, Kennette W et al.: Epigenetic mapping and functional analysis in a breast cancer metastasis model using whole-genome promoter tiling microarrays. Breast Cancer Res. 10, R62 (2008).
102. Azhikina T, Gainetdinov I, Skvortsova Y, Sverdlov E: Methylation-free site patterns along a 1-Mb locus on Chr19 in cancerous and normal cells are similar. A new fast approach for analyzing unmethylated CCGG sites distribution. Mol. Genet. Genomics 275, 615-622 (2006).
103. Frommer M, McDonald LE, Millar DS et al.: A genomic sequencing protocol that yields a positive display of 5-methylcytosine residues in individual DNA strands. Proc. Natl Acad. Sci. USA 89, 1827-1831 (1992).
104. Laird CD, Pleasant ND, Clark AD et al.: Hairpin-bisulfite PCR: assessing epigenetic methylation patterns on complementary strands of individual DNA molecules. Proc. Natl Acad. Sci. USA 101, 204-209 (2004).
105. Nishiyama R, Qi L, Lacey M, Ehrlich M: Both hypomethylation and hypermethylation in a 0.2-kb region of a DNA repeat in cancer. Mol. Cancer Res. 3, 617-626 (2005).
106. Shao C, Lacey M, Dubeau L, Ehrlich M: Hemimethylation footprints of DNA demethylation in cancer. Epigenetics 4, 165-175 (2009).
107. Novak P, Jensen TJ, Garbe JC, Stampfer MR, Futscher BW: Stepwise DNA methylation changes are linked to escape from defined proliferation barriers and mammary epithelial cell immortalization. Cancer Res. 69, 5251-5258 (2009).
108. Morey Kinney SR, Smiraglia DJ, James SR, Moser MT, Foster BA, Karpf AR: Stage-specific alterations of DNA methyltransferase expression, DNA hypermethylation, and DNA hypomethylation during prostate cancer progression in the transgenic adenocarcinoma of mouse prostate model. Mol Cancer Res. 6, 1365-1374 (2008).
109. Tsumagari K, Qi L, Jackson K et al.: Epigenetics of a tandem DNA repeat: chromatin DNasel sensitivity and opposite methylation changes in cancers. Nucleic Acids Res. 36, 2196-2207 (2008).
110. Choi SH, Worswick S, Byun HM et al.: Changes in DNA methylation of tandem DNA repeats are different from interspersed repeats in cancer. Int. J. Cancer 125, 723-729 (2009).
111. Pogribny IP, Miller BJ, James SJ: Alterations in hepatic p53 gene methylation patterns during tumor progression with folate/methyl deficiency in the rat. Cancer Lett. 115, 31-38 (1997).
112. Jacobsen SE, Meyerowitz EM: Hypermethylated SUPERMAN epigenetic alleles in Arabidopsis. Science 277, 1100-1103 (1997).
113. Lee HS, Kim BH, Cho NY et al.: Prognostic implications of and relationship between CpG island hypermethylation and repetitive DNA hypomethylation in hepatocellular carcinoma. Clin. Cancer Res. 15, 812-820 (2009).
114. Tryndyak VP, Kovalchuk O, Pogribny IP: Loss of DNA methylation and histone H4 lysine 20 trimethylation in human breast cancer cells is associated with aberrant expression of DNA methyltransferase 1, Suv4-20h2 histone methyltransferase and methyl-binding proteins. Cancer Biol. Ther. 5, 65-70 (2006).
115. Deng G, Nguyen A, Tanaka H et al.: Regional hypermethylation and global hypomethylation are associated with altered chromatin conformation and histone acetylation in colorectal cancer. Int. J. Cancer 118, 2999-3005(2006).
116. Nagarajan RP, Costello JF: Molecular epigenetics and genetics in neuro-oncology. Neurotherapeutics 6, 436-446 (2009).
117. Florl AR, Lower R, Schmitz-Drager BJ, Schulz WA: DNA methylation and expression of LINE-1 and HERV-K provirus sequences in urothelial and renal cell carcinomas. Br. J. Cancer 80, 1312-1321 (1999).
118. Katargin AN, Pavlova LS, Kisseljov FL, Kisseljova NP: Hypermethylation of genomic 3.3-kb repeats is frequent event in HPV-positive cervical cancer. BMC Med. Genomics 2, 30 (2009).
119. Ehrlich M: Cancer-linked DNA hypomethylation and its relationship to hypermethylation. Curr. Top. Microbiol. Immunol. 310, 251-274 (2006).
120. Clark SJ: Action at a distance: epigenetic silencing of large chromosomal regions in carcinogenesis. Hum. Mol. Genet. 16(Spec. 1,) R88-R95 (2007).
121. Cheng CW, Wu PE, Yu JC et al.: Mechanisms of inactivation of E-cadherin in breast carcinoma: modification of the two-hit hypothesis of tumor suppressor gene. Oncogene 20, 3814-3823 (2001).
122. Taniguchi T, Tischkowitz M, Ameziane N et al.: Disruption of the Fanconi anemia-BRCA pathway in cisplatin-sensitive ovarian tumors. Nat. Med. 9, 568-574 (2003).
123. Saluz HP, Jiricny J, Jost JP: Genomic sequencing reveals a positive correlation between the kinetics of strand-specific DNA demethylation of the overlapping estradiol/glucocorticoid-receptor binding sites and the rate of avian vitellogenin mRNA synthesis. Proc. Natl Acad. Sci. USA 83, 7167-7171 (1986).
124. Pfeifer GP, Steigerwald SD, Hansen RS, Gartier SM, Riggs AD: Polymerase chain reaction-aided genomic sequencing of an X chromosome-linked CpG island: methylation patterns suggest clonal inheritance, CpG site autonomy, and an explanation of activity state stability. Proc. Natl Acad. Sci. USA 87, 8252-8256 (1990).
125. Barreto G, Schafer A, Marhold J et al.: Gadd45a promotes epigenetic gene activation by repair-mediated DNA demethylation. Nature 445, 671-675 (2007).
126. Niehrs C: Active demethylation and DNA repair. Differentiation 11, 1-11 (2009).
127. Miller CA, Campbell SL, Sweatt JD: DNA methylation and histone acetylation work in concert to regulate memory formation and synaptic plasticity. Neurobiol. Learn. Mem. 89, 599-603 (2008).
128. Metivier R, Gallais R, Tiffoche C et al: Cyclical DNA methylation of a transcriptionally active promoter. Nature 452, 45-50 (2008).
129. Riclet R, Chendeb M, Vonesch JL et al: Disruption of the interaction between transcriptional intermediary factor 1(β) and heterochromatin protein 1 leads to a switch from DNA hyper- to hypomethylation and H3K9 to H3K27 trimethylation on the M EST promoter correlating with gene reactivation. Mol Biol. Cell. 20, 296-305 (2009).
130. Yegnasubramanian S, Haffner MC, Zhang Y et al: DNA hypomethylation arises later in prostate cancer progression than CpG island hypermethylation and contributes to metastatic tumor heterogeneity. Cancer Res. 68, 8954-8967 (2008).
131. Carr BI, Reilly G, Smith SS, Winberg C, Riggs A: The tumorigenicity of 5-azacytidine in the male Fisher rat. Carcinogenesis 5, 1583-1590 (1984).
132. Thomas GA, Williams ED: Production of thyroid tumours in mice by demethytating agents. Carcinogenesis 13, 1039-1042 (1992).
133. Denda A, Rao PM, Rajalakshmi S, Sarma DS: 5-azacytidine potentiates initiation induced by carcinogens in rat liver. Carcinogenesis 6, 145-146 (1985).
134. Gaudet F, Hodgson JG, Eden A et al.: Induction of tumors in mice by genomic hypomethylation. Science 300, 489-492 (2003).
135. Yamada Y, Jackson-Grusby L, Linhart H et al: Opposing effects of DNA hypomethylation on intestinal and liver carcinogenesis. Proc. Natl Acad. Sci. USA 102, 13580-13585 (2005).
136. Poirier LA: Methyl group deficiency in hepatocarcinogenesis. Drug Metab. Rev. 26, 185-199 (1994).
137. Pogribny IP, Basnakian AG, Miller BJ, Lopatina NG, Poirier LA, James SJ: Breaks in genomic DNA and within the p53 gene are associated with hypomethylation in livers of folate/methyl-deficient rats. Cancer Res. 55, 1894-1901 (1995).
138. Pogribny IP, Ross SA, Wise C et al.: Irreversible global DNA hypomethylation as key step in hepatocarcinogenesis induced by dietary methyl deficiency. Mutat. Res. 593, 80-87 (2006).
139. Cooney CA, Dave AA, Wolff GL: Maternal methyl supplements in mice affect epigenetic variation and DNA methylation of offspring. J. Nutr. 132, S2393-S2400 (2002).
140. Dolinoy DC, Weidman JR, Waterland RA, Jirtle RL: Maternal genistein alters coat color and protects Avy mouse offspring from obesity by modifying the fetal epigenome. Environ. Health Perspect. 114, 567-572 (2006).
141. Toffoli G, De Mattia E: Pharmacogenetic relevance of MTHFR polymorphisms. Pharmacogenomics 9, 1195-1206 (2008).
142. Linhart HG, Troen A, Bell GW et al.: Folate deficiency induces genomic uracil misincorporation and hypomethylation but does not increase DNA point mutations. Gastroenterology 136, 227-235 (2009).
143. Laird PW, Jackson-Grusby L, Fazeli A et al.: Suppression of intestinal neoplasia by DNA hypomethylation. Cell 81, 197-205 (1995).
144. Lin H, Yamada Y, Nguyen S et al.: Suppression of intestinal neoplasia by deletion of Dnmt3b. Mol. Cell. Biol. 26, 2976-2983 (2006).
145. Holm TM, Jackson-Grusby L, Brambrink T, Yamada Y, Rideout WM 3rd, Jaenisch R: Global loss of imprinting leads to widespread tumorigenesis in adult mice. Cancer Cell 8, 275-285 (2005).
146. Howard G, Eiges R, Gaudet F, Jaenisch R, Eden A: Activation and transposition of endogenous retroviral elements in hypomethylation induced tumors in mice. Oncogene 27, 404-408 (2008).
147. Pogribny IP, Beland FA: DNA hypomethylation in the origin and pathogenesis of human diseases. Cell. Mol. Life Sci. 66, 2249-2261 (2009).
148. Tycko B: Genomic imprinting and human neoplasia. In: DNA and Alterations in Cancer: Genetic and Epigenetic Alterations. Ehrlich M (Ed.), Eaton Publishing, MA, USA, 333-349 (2000).
149. Czekierdowski A, Czekierdowska S, Wielgos M, Smolen A, Kaminski P, Kotarski J: The role of CpG islands hypomethylation and abnormal expression of neuronal protein synuclein-y (SNCG) in ovarian cancer. Neuro Endocrinol Lett. 27, 381-386 (2006).
150. Zhao W, Liu H, Liu W et al.: Abnormal activation of the synuclein-γ gene in hepatocellular carcinomas by epigenetic alteration. Int. J. Oncol. 28, 1081-1088 (2006).
151. Liu H, Liu W, Wu Y et al.: Loss of epigenetic control of synuclein-y gene as a molecular indicator of metastasis in a wide range of human cancers. Cancer Res. 65, 7635-7643 (2005).
152. Chekhun VF, Lukyanova NY, Kovalchuk O, Tryndyak VP, Pogribny IP: Epigenetic profiling of multidrug-resistant human MCF-7 breast adenocarcinoma cells reveals novel hyper- and hypomethylated targets. Mol. Cancer Ther. 6, 1089-1098 (2007).
153. Shen R, Tao L, Xu Y, Chang S, Van Brocklyn J, Gao JX: Reversibility of aberrant global DNA and estrogen receptor-α gene methylation distinguishes colorectal precancer from cancer. Int. J. Clin. Exp. Pathol. 2, 21-33 (2009).
154. Kokalj-Vokac N, Almeida A, Viegas-Pequignot E, Jeanpierre M, Malfoy B, Dutrillaux B: Specific induction of uncoiling and recombination by azacytidine in classical satellite-containing constitutive heterochromatin. Cytogenet. Cell Genet. 63, 11-15(1993).
155. Ji W, Hernandez R, Zhang X-Y et al.: DNA demethylation and pericentromeric rearrangements of chromosome 1. Mutat. Res. 379, 33-41 (1997).
156. Chen RZ, Pettersson U, Beard C, Jackson-Grusby L, Jaenisch R: DNA hypomethylation leads to elevated mutation rates. Nature 395, 89-93 (1998).
157. Wong N, Lam WC, Lai PB, Pang E, Lau WY, Johnson PJ: Hypomethylation of chromosome 1 heterochromatin DNA correlates with q-arm copy gain in human hepatocellular carcinoma. Am. J. Pathol. 159, 465-471 (2001).
158. Eden A, Gaudet F, Waghmare A, Jaenisch R: Chromosomal instability and tumors promoted by DNA hypomethylation. Science 300, 455 (2003).
159. Jeanpierre M, Turleau C, Aurias A et al.: An embryonic-like methylation pattern of classical satellite DNA is observed in ICF syndrome. Hum. Mol. Genet. 2, 731-735 (1993).
160. Tuck-Muller CM, Narayan A, Tsien F et al.: DNA hypomethylation and unusual chromosome instability in cell lines from ICF syndrome patients. Cytogenet. Cell Genet. 89, 121-128 (2000).
161. Vilain A, Bernardino J, Gerbault-Seureau M et al.: DNA methylation and chromosome instability in lymphoblastoid cell lines. Cytogenet. Cell Genet. 90, 93-101 (2000).
162. Tsien F, Youn B, Fiala ES et al.: Prolonged culture of chorionic villus cells yields ICF syndrome-like chromatin decondensation and rearrangements. Cytogen. Genome Res. 98, 13-21 (2002).
163. Mitelman F, Mertens F, Johansson B: A breakpoint map of recurrent chromosomal rearrangements in human neoplasia. Nat. Genet. 15(Spec), 417-474 (1997).
164. Ehrlich M: DNA methylation and cancer-associated genetic instability. In: Genome Instability and Cancer. Nigg E (Ed.), Kluwer, NY, USA (2004).
165. Schulz WA, Elo JP, Florl AR et al.: Genome-wide DNA hypomethylation is associated with alterations on chromosome 8 in prostate carcinoma. Genes Chromosomes Cancer 35, 58-65 (2002).
166. Ehrlich M, Ehrlich KC: Effect of DNA methylation on the binding of vertebrate and plant proteins to DNA. In: DNA Methylation: Biological Significance. Jost JP, Saluz HP (Eds), Birkhauser Verlag, MA, USA, 145-168 (1993).
167. Wade PA: Methyl CpG binding proteins: coupling chromatin architecture to gene regulation. Oncogene 20, 3166-3173 (2001).
168. Fuks F, Hurd PJ, Wolf D, Nan X, Bird AP, Kouzarides T: The methyl-CpG-binding protein MeCP2 links DNA methylation to histone methylation. J. Biol. Chem. 278, 4035-4040 (2003).
169. Xu Y, Sengupta PK, Seto E, Smith BD: Regulatory factor for X-box family proteins differentially interact with histone deacetylases to repress collagen α2(1) gene (COL1A2) expression. J. Biol. Chem. 281, 9260-9270 (2006).
170. Sabbattini P, Lundgren M, Georgiou A, Chow C, Warnes G, Dillon N: Binding of Ikaros to the lambda5 promoter silences transcription through a mechanism that does not require heterochromatin formation. EMBO J. 20, 2812-2822 (2001).
171. Gibbons RJ, McDowell TL, Raman S et al.: Mutations in ATRX, encoding a SWI/SNF-like protein, cause diverse changes in the pattern of DNA methylation. Nat. Genet. 24, 368-371 (2000).
172. Denegri M, Moralli D, Rocchi M et al.: Human chromosomes 9, 12, and 15 contain the nucleation sites of stress-induced nuclear bodies. Mol. Biol. Cell 13, 2069-2079 (2002).
173. Tang QQ, Lane MD: Activation and centromeric localization of CCAAT/enhancer-binding proteins during the mitotic clonal expansion of adipocyte differentiation. Genes Dev. 13, 2231-2241 (1999).
174. Bozhenok L, Wade PA, Varga-Weisz P: WSTF-ISWI chromatin remodeling complex targets heterochromatic replication foci. EMBO J. 21, 2231-2241 (2002).
175. Bachman KE, Rountree MR, Baylin SB: Dnmt3a and Dnmt3b are transcriptional repressors that exhibit unique localization properties to heterochromatin. J. Biol. Chem. 276, 32282-32287 (2001).
176. Craig JM, Earle E, Canham P, Wong LH, Anderson M, Choo KH: Analysis of mammalian proteins involved in chromatin modification reveals new metaphase centromeric proteins and distinct chromosomal distribution patterns. Hum. Mol. Genet. 12, 3109-3121 (2003).
177. Nan X, Tate P, Li E, Bird A: DNA methylation specifies chromosomal localization of MeCP2. Mol. Cell. Biol. 16, 414-421 (1996).
178. Cammas F, Oulad-Abdelghani M, Vonesch JL, Huss-Garcia Y, Chambon P, Losson R: Cell differentiation induces TIF1β association with centromeric heterochromatin via an HP1 interaction. J. Cell Sci. 115, 3439-3448 (2002).
179. Jolly C, Metz A, Govin J et al.: Stress-induced transcription of satellite 111 repeats. J. Cell Biol. 164, 25-33 (2004).
180. Gasser SM: Positions of potential: nuclear organization and gene expression. Cell 104, 639-642 (2001).
181. Kosak ST, Skok JA, Medina KL et al.: Subnuclear compartmentalization of immunoglobulin loci during lymphocyte development. Science 296, 158-162 (2002).
182. Papait R, Pistore C, Grazini U et al.: The PHD domain of Np95 (mUHRFl) is involved in large-scale reorganization of pericentromeric heterochromatin. Mol. Biol. Cell 19, 3554-3563 (2008).
183. Enukashvily NI, Malashicheva AB, Waisertreiger IS: Satellite DNA spatial localization and transcriptional activity in mouse embryonic E-14 and IOUD2 stem cells. Cytogenet. Genome Res. 124, 277-287 (2009).
184. Volpe TA, Kidner C, Hall IM, Teng G, Grewal SI, Martienssen RA: Regulation of heterochromatic silencing and histone H3 lysine-9 methylation by RNAi. Science 297, 1833-1837 (2002).
185. Rizzi N, Denegri M, Chiodi I et al.: Transcriptional activation of a constitutive heterochromatic domain of the human genome in response to heat shock. Mol. Biol. Cell 15, 543-551 (2004).
186. Iorio MV, Visone R, Di Leva G et al.: MicroRNA signatures in human ovarian cancer. Cancer Res. 67, 8699-8707 (2007).
187. Lee KH, Lotterman C, Karikari C et al.: Epigenetic silencing of MicroRNA miR-107 regulates cyclin-dependent kinase 6 expression in pancreatic cancer. Pancreatology 9, 293-301 (2009).
188. Delcuve GP, Rastegar M, Davie JR: Epigenetic control. J. Cell Physiol. 219, 243-250 (2009).
189. Widschwendter M, Fiegl H, Egle D et al.: Epigenetic stem cell signature in cancer. Nat. Genet. 39, 157-158 (2007).
190. Werbowetski-Ogilvie TE, Bhatia M: Pluripotent human stem cell lines: what we can learn about cancer initiation. Trends Mol. Med. 14, 323-332 (2008).
191. Meissner A, Mikkelsen TS, Gu H et al.: Genome-scale DNA methylation maps of pluripotent and differentiated cells. Nature 454, 766-770 (2008).
192. Gowher H, Stuhlmann H, Felsenfeld G: Vezfl regulates genomic DNA methylation through its effects on expression of DNA methyltransferase Dnmt3b. Genes Dev. 22, 2075-2084 (2008).
193. Chapman V, Forrester L, Sanford J, Hastie N, Rossant J: Cell lineage-specific undermethylation of mouse repetitive DNA. Nature 307, 284-286 (1984).
194. Sanford JP, Clark HJ, Chapman VM, Rossant J: Differences in DNA methylation during oogenesis and spermatogenesis and their persistence during early embryogenesis in the mouse. Genes Dev. 1, 1039-1046(1987).
195. Jost J P, Oakeley EJ, Zhu B et al.: 5-methylcytosine DNA glycosylase participates in the genome-wide loss of DNA methylation occurring during mouse myoblast differentiation. Nucleic Acids Res. 29, 4452-4461 (2001).
196. Mayer W, Niveleau A, Walter J, Fundele R, Haaf T: Demethylation of the zygotic paternal genome. Nature 403, 501-502 (2000).
197. Oswald J, Engemann S, Lane N et al.: Active demethylation of the paternal genome in the mouse zygote. Curr. Biol. 10, 475-478 (2000).
198. Santos F, Hendrich B, Reik W, Dean W: Dynamic reprogramming of DNA methylation in the early mouse embryo. Dev. Biol. 241, 172-182(2002).
199. Park JS, Jeong YS, Shin ST, Lee KK, Kang YK: Dynamic DNA methylation reprogramming: active demethylation and immediate remethylation in the male pronucleus of bovine zygotes. Dev. Dyn. 236, 2523-2533 (2007).
200. Zhu J, Kapoor A, Sridhar VV, Agius F, Zhu JK: The DNA glycosylase/lyase ROSI functions in pruning DNA methylation patterns in Arabidopsis. Curr. Biol. 17, 54-59 (2007).
201. Bhattacharya SK, Ramchandani S, Cervoni N, Szyf M: A mammalian protein with specific demethylase activity for mCpG DNA. Nature 397, 579-583 (1999).
202. Jin SG, Guo C, Pfeifer GP: GADD45A does not promote DNA demethylation. PLoS Genet. 4, E1000013 (2008).
203. Ooi SK, Bestor TH: The colorful history of active DNA demethylation. Cell 133, 1145-1148(2008).
204. Vilkaitis G, Suetake I, Klimasauskas S, Tajima S: Processive methylation of hemimethylated CpG sites by mouse Dnmtl DNA methyltransferase. J. Biol. Chem. 280, 64-72 (2005).
205. Bostick M, Kim JK, Esteve PO, Clark A, Pradhan S, Jacobsen SE: UHRF1 plays a role in maintaining DNA methylation in mammalian cells. Science 317, 1760-1764 (2007).
206. Jeltsch A: On the enzymatic properties of Dnmtl: specificity, processivity, mechanism of linear diffusion and allosteric regulation of the enzyme. Epigenetics 1, 63-66 (2006).
207. Orend G, Kuhlmann I, Doerfler W: Spreading of DNA methylation across integrated foreign (adenovirus type 12) genomes in mammalian cells. J. Virol. 65, 4301-4308 (1991).
208. Porecha RH, Stivers JT: Uracil DNA glycosylase uses DNA hopping and short-range sliding to trap extrahelical uracils. Proc. Natl Acad. Sci. USA 105, 10791-10796 (2008).
209. Lacey M, Ehrlich M: Modeling dependence in methylation patterns with application to ovarian carcinomas. Stat. Appl. Genet. Mol. Biol. 8, 40 (2009).
210. Handa V, Jeltsch A: Profound flanking sequence preference of Dnmt3a and Dnmt3b mammalian DNA methyltransferases shape the human epigenome. J. Mol. Biol. 348, 1103-1112(2005).
211. Garzon R, Liu S, Fabbri M et al.: MicroRNA-29b induces global DNA hypomethylation and tumor suppressor gene reexpression in acute myeloid leukemia by targeting directly DNMT3A and 3B and indirectly DNMT1. Blood 113, 6411-6418 (2009).
212. De La Fuente R, Baumann C, Fan T, Schmidtmann A, Dobrinski I, Muegge K: Lsh is required for meiotic chromosome synapsis and retrotransposon silencing in female germ cells. Nat. Cell Biol. 8, 1448-1454 (2006).
213. Ostler KR, Davis EM, Payne SL et al: Cancer cells express aberrant DNMT3B transcripts encoding truncated proteins. Oncogene 26, 5553-5563 (2007).
214. Nimura K, Ishida C, Koriyama H et al: Dnmt3a2 targets endogenous Dnmt3L to ES cell chromatin and induces regional DNA methylation. Genes Cells 11, 1225-1237 (2006).
215. Weisenberger DJ, Velicescu M, Cheng JC, Gonzales FA, Liang G, Jones PA: Role of the DNA methyltransferase variant DNMT3b3 in DNA methylation. Mol. Cancer Res. 2, 62-72 (2004).
216. Jiang YL, Rigolet M, Bourc'his D et al.: DNMT3B mutations and DNA methylation defect define two types of ICF syndrome. Hum. Mutat. 25, 56-63 (2005).
217. Caiafa P, Guastafierro T, Zampieri M: Epigenetics: poly(ADP-ribosyl)ation of PARP-1 regulates genomic methylation patterns. FASEB J. 23, 672-678 (2009).
218. Minarovits J: Microbe-induced epigenetic alterations in host cells: the coming era of patho-epigenetics of microbial infections. A review. Acta Microbiol. Immunol. Hung. 56, 1-19 (2009).
219. Piyathilake CJ, Frost AR, Bell WC et al.: Altered global methylation of DNA: an epigenetic difference in susceptibility for lung cancer is associated with its progression. Hum. Pathol. 32, 856-862(2001).
220. Hernandez-Blazquez FJ, Habib M, Dumollard JM et al: Evaluation of global DNA hypomethylation in human colon cancer tissues by immunohistochemistry and image analysis. Gut 47, 689-693 (2000).
221. Galusca B, Dumollard JM, Lassandre S et al.: Global DNA methylation evaluation: potential complementary marker in differential diagnosis of thyroid neoplasia. Virchows Arch. 447, 18-23 (2005).
222. Lubbert M, Wijermans P, Kunzmann R et al: Cytogenetic responses in high-risk myelodysplastic syndrome following low-dose treatment with the DNA methylation inhibitor 5-aza-2'-deoxycytidine. Br. J. Haematol. 114, 349-357 (2001).
223. Silverman LR, Demakos EP, Peterson BL et al.: Randomized controlled trial of azacitidine in patients with the myelodysplastic syndrome: a study of the cancer and leukemia group B. J. Clin. Oncol. 20, 2429-2440 (2002).
224. Mack GS: Epigenetic cancer therapy makes headway. J. Natl Cancer Inst. 98, 1443-1444 (2006).
225. Sessa C, ten Bokkel Huinink W, Stoter G, Renard J, Cavalli F: Phase II study of 5-aza-2'-deoxycytidine in advanced ovarian carcinoma. The EORTC Early Clinical Trials Group. Eur. J. Cancer 26, 137-138 (1990).
226. Vermorken JB, Tumolo S, Roozendaal KJ, Guastalla JP, Splinter TA, Renard J: 5-aza-2'-deoxycytidine in advanced or recurrent cancer of the uterine cervix. Eur. J. Cancer 27, 216-217(1991).
227. Aparicio A, Weber JS: Review of the clinical experience with 5-azacytidine and 5-aza-2'-deoxycytidine in solid tumors. Curr. Opin. Investig. Drugs 3, 627-633 (2002).
228. Silverman LR: Targeting hypomethylation of DNA to achieve cellular differentiation in myelodysplastic syndromes (MDS). Oncologist 6, 8-14(2001).
229. Kornblith AB, Herndon JE 2nd, Silverman LR et al: Impact of azacytidine on the quality of life of patients with myelodysplastic syndrome treated in a randomized Phase III trial: a Cancer and Leukemia Group B study. J. Clin. Oncol. 20, 2441-2452 (2002).
230. Kantarjian H, Oki Y, Garcia-Manero G et al: Results of a randomized study of 3 schedules of low-dose decitabine in higher-risk myelodysplastic syndrome and chronic myelomonocytic leukemia. Blood 109, 52-57 (2007).
231. Garcia-Manero G, Kantarjian HM, Sanchez-Gonzalez B et al.: Phase 1/2 study of the combination of 5-aza-2'-deoxycytidine with valproic acid in patients with leukemia. Blood 108, 3271-3279 (2006).
232. Issa JP, Gharibyan V, Cortes J et al.: Phase II study of low-dose decitabine in patients with chronic myelogenous leukemia resistant to imatinib mesylate. J. Clin. Oncol. 23, 3948-3956 (2005).
233. Reu FJ, Bae SI, Cherkassky L et al.: Overcoming resistance to interferon-induced apoptosis of renal carcinoma and melanoma cells by DNA demethylation. J. Clin. Oncol. 24, 3771-3779 (2006).
234. Gore SD, Baylin S, Sugar E et al.: Combined DNA methyltransferase and histone deacetylase inhibition in the treatment of myeloid neoplasms. Cancer Res. 66, 6361-6369 (2006).
235. Koschmieder S, Agrawal S, Radomska HS et al.: Decitabine and vitamin D3 differentially affect hematopoietic transcription factors to induce monocytic differentiation. Int. J. Oncol. 30, 349-355 (2007).
236. Watanabe Y, LePage S, Elliott M et al.: Characterization of preexisting humoral immunity specific for two cancer-testis antigens overexpressed at the mRNA level in non-small cell lung cancer. Cancer Immun. 6, 3 (2006).
237. Hoeppner LH, Dubovsky JA, Dunphy EJ, McNeel DG: Humoral immune responses to testis antigens in sera from patients with prostate cancer. Cancer Immun. 6, 1 (2006).
238. Karpf AR, Lasek AW, Ririe TO, Hanks AN, Grossman D, Jones DA: Limited gene activation in tumor and normal epithelial cells treated with the DNA methyltransferase inhibitor 5-aza-2'-deoxycytidine. Mot. Pharmacol. 65, 18-27 (2004).
239. Dubovsky JA, McNeel DG, Powers JJ, Gordon J, Sotomayor EM, Pinilla-Ibarz JA: Treatment of chronic lymphocytic leukemia with a hypomethylating agent induces expression of NXF2, an immunogenic cancer testis antigen. Clin. Cancer Res. 15, 3406-3415 (2009).
240. Gjerstorff MF, Johansen LE, Nielsen O, Kock K, Ditzel HJ: Restriction of GAGE protein expression to subpopulations of cancer cells is independent of genotype and may limit the use of GAGE proteins as targets for cancer immunotherapy. Br. J. Cancer 94, 1864-1873 (2006).
241. Mund C, Hackanson B, Stresemann C, Lubbert M, Lyko F: Characterization of DNA demethylation effects induced by 5-aza-2'-deoxycytidine in patients with myelodysplastic syndrome. Cancer Res. 65, 7086-7090 (2005).
242. Garcia-Manero G: Demethylating agents in myeloid malignancies. Curr. Opin. Oncol. 20, 705-710(2008).
243. Daskalakis M, Nguyen TT, Nguyen C et al: Demethylation of a hypermethylated P15/INK4B gene in patients with myelodysplastic syndrome by 5-aza-2'-deoxycytidine (decitabine) treatment. Blood 100, 2957-2964 (2002).
244. Yang AS, Doshi KD, Choi SW et al.: DNA methylation changes after 5-aza-2'-deoxycytidine therapy in patients with leukemia. Cancer Res. 66, 5495-5503 (2006).
245. Davidson S, Crowther P, Radley J, Woodcock D: Cytotoxicity of 5-aza-2'-deoxycytidine in a mammalian cell system. Eur. J. Cancer 25, 362-368 (1992).
246. Juttermann R, Li E, Jaenisch R: Toxicity of 5-aza-2'-deoxycytidine to mammalian cells is mediated primarily by covalent trapping of DNA methyltransferase rather than DNA demethylation. Proc. Natl Acad. Sci. USA 91, 11797-11801 (1994).
247. Scott SA, Dong WF, Ichinohasama R et al.: 5-aza-2'-deoxycytidine (decitabine) can relieve p21WAF1 repression in human acute myeloid leukemia by a mechanism involving release of histone deacetylase 1 (HDAC1) without requiring p21WAFl promoter demethylation. Leuk. Res. 30, 69-76 (2006).
248. Fandy TE: Development of DNA methyltransferase inhibitors for the treatment of neoplastic diseases. Curr. Med. Chem. 16, 2075-2085 (2009).
249. Jackson-Grusby L, Laird PW, Magge SN, Moeller BJ, Jaenisch R: Mutagenicity of 5-aza-2'-deoxycytidine is mediated by the mammalian DNA methyltransferase. Proc. Natl Acad. Sci. USA 94, 4681-4685 (1997).
250. Ehrlich M, Jiang G: DNA Hypovs hypermethylation in cancer: tumor specificity, tumor progression, and therapeutic implications. In: DNA Methylation and Cancer. Szyf M (Ed.). Kluwer Academic/Plenum Publishers and Landes Bioscience/Eurekah.com, Washington, DC, USA (2003).
251. Gene cards website www.genecards.org